0 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
These are activities that require reflection on feedback about your work.
These are activities that use your work data to ensure quality results.
As our population continues to age, the number of people with dementia is set to skyrocket, a situation that geriatric medicine researcher A/Prof Michael Woodward has likened to a ‘tsunami that’s sadly almost bearing down on us’.
Dementia already affects more than 400,000 Australians and is the second-biggest cause of death, but it’s predicted that this will grow to 589,000 by 2028 and more than one million by 2058.
The debilitating condition causes a decline in memory, cognition and day-to-day functioning, a distressing process both for sufferers and their loved ones.
Two new medications for dementia are currently being trialled, giving hope for more effective treatment. One is a monoclonal antibody gantenerumab, designed to remove the toxic protein amyloid from the brains of people with dementia. Although earlier trials have been disappointing, a higher dose is now being trialled in several thousand participants, including at Melbourne’s Austin Hospital.
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease
